Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.
Humans
Double-Blind Method
Female
Adult
Male
Dose-Response Relationship, Drug
Cross-Over Studies
Heart Rate
/ drug effects
Blood Pressure
/ drug effects
Mescaline
/ administration & dosage
Ketanserin
/ pharmacology
Hallucinogens
/ administration & dosage
Young Adult
Healthy Volunteers
Serotonin 5-HT2 Receptor Antagonists
/ pharmacokinetics
Nausea
/ chemically induced
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
06
03
2024
accepted:
23
09
2024
revised:
20
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking. Additionally, its mechanism of action has not been investigated in humans. We used a randomized, double-blind, placebo-controlled, crossover design in 16 healthy subjects (8 women) who received placebo, mescaline (100, 200, 400, and 800 mg), and 800 mg mescaline together with the serotonin 5-hydroxytryptamine-2A (5-HT
Identifiants
pubmed: 39349427
doi: 10.1038/s41398-024-03116-2
pii: 10.1038/s41398-024-03116-2
doi:
Substances chimiques
Mescaline
RHO99102VC
Ketanserin
97F9DE4CT4
Hallucinogens
0
Serotonin 5-HT2 Receptor Antagonists
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
395Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 32003B_185111
Informations de copyright
© 2024. The Author(s).
Références
La Barre W. Peyotl and mescaline. J Psychedelic Drugs. 1979;11:33–9.
doi: 10.1080/02791072.1979.10472090
pubmed: 392117
Cassels BK, Saez-Briones P. Dark classics in chemical neuroscience: mescaline. ACS Chem Neurosci. 2018;9:2448–58.
doi: 10.1021/acschemneuro.8b00215
pubmed: 29847089
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809.
doi: 10.1016/j.eclinm.2022.101809
Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843–53.
doi: 10.1001/jama.2023.14530
pubmed: 37651119
pmcid: 10472268
Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48:1492–99.
doi: 10.1038/s41386-023-01648-7
pubmed: 37443386
pmcid: 10425429
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.
doi: 10.1056/NEJMoa2032994
pubmed: 33852780
Holze F, Gasser P, Muller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93:215–23.
doi: 10.1016/j.biopsych.2022.08.025
pubmed: 36266118
Bruhn JG, De Smet PA, El-Seedi HR, Beck O. Mescaline use for 5700 years. Lancet. 2002;359:1866.
doi: 10.1016/S0140-6736(02)08701-9
pubmed: 12044415
Beringer K. Der Meskalinrausch. Berlin: Springer; 1927.
Guttmann E. Artificial psychoses produced by mescaline. J Ment Sci. 1936;82:204–21.
doi: 10.1192/bjp.82.338.203
Guttmann E, Maclay WS. Mescaline and depersonalization: therapeutic experiments. J Neurol Psychopathol. 1936;16:193–212.
doi: 10.1136/jnnp.s1-16.63.193
pubmed: 21610826
pmcid: 1038999
Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry. 1992;32:976–91.
doi: 10.1016/0006-3223(92)90059-9
pubmed: 1467389
Unger SM. Mescaline, LSD, psilocybin, and personality change. Psychiatry. 1963;26:111–25.
doi: 10.1080/00332747.1963.11023344
pubmed: 13995386
Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023;48:1659–67.
doi: 10.1038/s41386-023-01607-2
pubmed: 37231080
pmcid: 10517157
Friedrichs H, Dierssen O, Passie T. Die Psychologie des Meskalinrausches. VWB, Verlag für Wiss. und Bildung; Berlin, 2009.
Laing R, Laing RR, Beyerstein BL, Siegel JA. Hallucinogens: a forensic drug handbook. Academic Press; San Diego, 2003.
Holze F, Vizeli P, Ley L, Muller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46:537–44.
doi: 10.1038/s41386-020-00883-6
pubmed: 33059356
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451–57.
doi: 10.1016/j.cub.2016.12.030
pubmed: 28132813
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897–902.
doi: 10.1097/00001756-199812010-00024
pubmed: 9875725
Valle M, Maqueda AE, Rabella M, Rodriguez-Pujadas A, Antonijoan RM, Romero S, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol. 2016;26:1161–75.
doi: 10.1016/j.euroneuro.2016.03.012
pubmed: 27039035
Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol. 2023;26:97–106.
doi: 10.1093/ijnp/pyac075
pubmed: 36342343
Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462–71.
doi: 10.1038/s41386-019-0569-3
pubmed: 31733631
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.
doi: 10.1016/j.biopsych.2014.11.015
pubmed: 25575620
Janke W, Debus G. Die Eigenschaftswörterliste. Göttingen: Hogrefe; 1978.
Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80–4.
doi: 10.1055/s-2007-979351
pubmed: 9754838
Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010;5:e12412.
doi: 10.1371/journal.pone.0012412
pubmed: 20824211
pmcid: 2930851
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–83.
doi: 10.1007/s00213-006-0457-5
pubmed: 16826400
Liechti ME, Dolder PC, Schmid Y. Alterations in conciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. 2017;234:1499–510.
doi: 10.1007/s00213-016-4453-0
pubmed: 27714429
Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29:1182–90.
doi: 10.1177/0269881115609019
pubmed: 26442957
pmcid: 5203697
Hysek CM, Vollenweider FX, Liechti ME. Effects of a b-blocker on the cardiovascular response to MDMA (ecstasy). Emerg Med J. 2010;27:586–89.
doi: 10.1136/emj.2009.079905
pubmed: 20378736
Thomann J, Ley L, Klaiber A, Liechti ME, Duthaler U. Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma. J Pharm Biomed Anal. 2022;220:114980.
doi: 10.1016/j.jpba.2022.114980
pubmed: 35963018
R Core Team. R: A language and environment for statistical computing. 2023.
Holze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, Liechti ME. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 2019;85:1474–83.
doi: 10.1111/bcp.13918
pubmed: 30883864
pmcid: 6595343
Zerssen DV. Die Beschwerden-Liste. Münchener Informationssystem. München: Psychis; 1976.
Holze F, Ley L, Muller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7.
doi: 10.1038/s41386-022-01297-2
pubmed: 35217796
pmcid: 9018810
Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of Peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 2019;12:184–94.
doi: 10.2174/1874467211666181010154139
pubmed: 30318013
pmcid: 6864602
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546–53.
doi: 10.1016/j.neuropharm.2015.08.034
pubmed: 26318099
Charalampous W, Kinross-Wright. Metabolic fate of mescaline in man. Psychopharmacologia. 1966;9:48–63.
doi: 10.1007/BF00427703
pubmed: 5989103
Persson B, Heykants J, Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet. 1991;20:263–79.
doi: 10.2165/00003088-199120040-00002
pubmed: 2036747
Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327–37.
doi: 10.1016/j.euroneuro.2016.05.001
pubmed: 27216487